COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02255162
Recruitment Status : Terminated (Slow Accrual)
First Posted : October 2, 2014
Last Update Posted : August 18, 2017
Celgene Corporation
Information provided by (Responsible Party):
Amir Fathi, Massachusetts General Hospital

Brief Summary:

This research study is evaluating the safety and tolerability of the drug lenalidomide in combination with and following mismatched related donor microtransplantation in high risk AML patients in first remission. This study also aims to define the maximum tolerated dose (MTD) of lenalidomide given in this setting.

Microtransplantation seeks to give the participant donor cells in hopes that those cells can attack the underlying cancer. However, since the donor cells do not replace all of the host cells, it can hopefully avoid many of the serious risks involved with standard transplant, including graft-vs.-host disease (GVHD) - a complication where the donor cells attack the participant's normal body. Recent studies have suggested that lenalidomide can help aid donor cells to attack cancer when given after a stem cell transplant. This trial is trying to see if lenalidomide can help encourage the attack of leukemia cells by donor cells given as part of microtransplantation.

The FDA (the U.S. Food and Drug Administration) has approved lenalidomide but it has been approved for other uses such as in the treatment of other cancers including multiple myeloma and non-Hodgkin lymphoma. Although lenalidomide has been studied in patients with AML, it has not been approved by the FDA for standard use in AML. Lenalidomide is a compound made by the Celgene Corporation. It has properties which could demonstrate antitumor effects. The exact antitumor mechanism of action of lenalidomide is unknown.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Acute Myelocytic Leukemia Acute Myelogenous Leukemia Acute Granulocytic Leukemia Acute Non-Lymphocytic Leukemia Drug: Lenalidomide Genetic: HLA-mismatched stem-cell Microtransplantation Drug: Cytarabine Phase 1

Detailed Description:

After the screening procedures confirm that the participant is eligible to participate in the research study. The participant will be given a study drug-dosing calendar.

The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well they have tolerated their doses. Participants will receive the following:

  • Cytarabine
  • Microtransplantation
  • Lenalidomide

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)
Actual Study Start Date : January 2015
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Lenalidomide

Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.

Participants will receive the following:

  • Cytarabine-intravenous, fixed dosage, given 5 times during cycle
  • HLA-mismatched stem-cell microtransplantation
  • Lenalidomide-administered daily per cycle
Drug: Lenalidomide
Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
Other Name: •Revlimid®

Genetic: HLA-mismatched stem-cell Microtransplantation
Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.

Drug: Cytarabine
Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
Other Names:
  • Cytosar-U ®
  • 1-β-Arabinofuranosylcytosine
  • Arabinosylcytosine
  • Cytosine arabinoside
  • Ara-C

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of lenalidomide after microtransplantation [ Time Frame: Baseline, 42 Days ]

Secondary Outcome Measures :
  1. Disease Free Survival [ Time Frame: 1 year ]
  2. Overall Survival [ Time Frame: 1 Year ]
  3. To assess immunomodulatory effects of this combination through measurement of T cell subsets by flow cytometric techniques and through microchimerism analysis at multiple points on study [ Time Frame: 2 Years ]
  4. To identify incidence and severity of acute and chronic graft versus host disease (GVHD). [ Time Frame: 2 Years ]
  5. To detect and categorize, according to severity, the cumulative incidences of toxicities [ Time Frame: 2 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Recipient Inclusion Criteria
  • Adults, aged 18 through 75 years of age, with pathologically confirmed acute myelogenous leukemia, in pathologically confirmed complete remission following anti-leukemic therapy.
  • AST, ALT and Alkaline Phosphatase <5x Upper Limit normal (ULN), direct bilirubin < 2.0 mg/dl.
  • Adequate renal function as defined by: calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault Formula) or serum Cr less than institution ULN (the elderly will often have < 60 GFR)
  • ECOG performance status 0-2.
  • Have a diagnosis of high-risk AML as established by a poor-risk karyotype, adverse risk by ELN criteria, a therapy-related AML, age ≥ 60 or with antecedent hematologic disorder
  • LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram
  • Patients, or appropriate designee, must be able to provide informed consent.
  • Must not have received systemic anti-neoplastic therapy, including radiotherapy within 14 days of study treatment.
  • Female patients of childbearing age must have negative pregnancy test.
  • Male subject agrees to use an acceptable method for contraception during the entire study treatment period and through 6 months after the last dose of lenalidomide.
  • All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program. If needed, patients should be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation.
  • Donor Inclusion Criteria
  • Haploidentical 1st-degree relative as defined by 3/6 or 4/6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age
  • ECOG performance status 0 or 1
  • Excellent health per conventional pre-donor history (medical and psychosocial evaluation)
  • No positive testing for viral infection (HbsAg, HIV, HCV)
  • Donor ability to understand and provide informed consent
  • Meets standard institutional criteria for GCSF mobilized PBSC donation

Exclusion Criteria:

  • Recipient Exclusion Criteria
  • Diagnosis of acute promyelocytic leukemia
  • Active refractory or relapsed acute leukemia
  • Prior use of fludarabine, as this agent has been associated with higher subsequent rates of graft versus host disease
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Uncontrolled intercurrent illness that would limit compliance with study requirements.
  • HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study drug. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy.
  • A diagnosis of active hepatitis B or C as defined by detectable viral load assays in the blood
  • Known hypersensitivity to thalidomide or lenalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking lenalidomide.
  • Significant cardiac disease as determined by the investigator including:

    • Known or suspected cardiac amyloidosis
    • Congestive heart failure of Class III or IV of the NYHA classification
    • Uncontrolled angina, hypertension or arrhythmia
    • Myocardial infarction in past 6 months
    • Any uncontrolled or severe cardiovascular disease
    • Prior cerebrovascular event with persistent neurologic deficit
  • Medical conditions that, in the investigator's opinion, would impose excessive risk to the subject.
  • Equal to or greater than grade 2 ataxia, cranial or peripheral neuropathy.
  • Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection.
  • Pregnant women are excluded from this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02255162

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Celgene Corporation
Layout table for investigator information
Principal Investigator: Amir Fathi, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Amir Fathi, Principal Investigators, Massachusetts General Hospital Identifier: NCT02255162    
Other Study ID Numbers: 14-265
First Posted: October 2, 2014    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Amir Fathi, Massachusetts General Hospital:
Acute Myeloid Leukemia (AML)
Acute Myelocytic Leukemia
Acute Myelogenous Leukemia
Acute Granulocytic Leukemia
Acute Non-Lymphocytic Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors